Skip to main content

Advertisement

Log in

Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer

  • Review Article
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

Therapeutic options for patients with head and neck squamous cell carcinoma include surgery, radiation and chemotherapy. The latter plays a major role in the treatment selection of recurrent, metastatic or therapy resistant tumours, these being some of the major challenges in head and neck oncology. For these patients, chemosensitivity and chemoresistance assays would be paramount to identify their individual therapy options. In this review, seven common assays will be described and discussed in the context of several studies. Further, a new assay will also be presented, currently being validated in a European Union funded project. Comparisons will be drawn to evaluate the sensitivity and specificity of these assays in identifying individual treatment options, and their potential implementation in head and neck malignancies will be discussed. There is an unmet demand for the development of ex vivo diagnostic tools that may predict response in head and neck cancer on the way towards an individualized treatment for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Houchens DP, Ovejera AA, Hrsg (1978) Proceedings of the symposium on the use of athymic (nude) mice in Cancer research, 1977. Fischer, New York

  3. Petty RD, Sutherland LA, Hunter EM et al (1995) Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin 10:29–34

    Article  CAS  PubMed  Google Scholar 

  4. Maenpaa JU, Heinonen E, Hinkka SM et al (1995) The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. Gynecol Oncol 57:294–298

    Article  CAS  PubMed  Google Scholar 

  5. Price KAR, Cohen EE (2012) Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 13:35–46

    Article  PubMed  Google Scholar 

  6. Burstein HJ, Mangu PB, Somerfield MR et al (2011) American society of clinical oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 29:3328–3330

    Article  PubMed  Google Scholar 

  7. Whitehouse PA, Knight LA, Di Nicolantonio F et al (2003) Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumour chemosensitivity assay (ATP-TCA). Anticancer Drugs 14:369–375

    Article  CAS  PubMed  Google Scholar 

  8. Hamburger AW, Salmon SE (1977) Primary bioassay of human tumour stem cells. Science 197:461–463

    Article  CAS  PubMed  Google Scholar 

  9. Ang KK, Sturgis EM (2012) Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 22:128–142

    Article  PubMed  Google Scholar 

  10. Hamburger A, Salmon SE (1977) Primary bioassay of human myeloma stem cells. J Clin Investig 60:846–854

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mirghani H, Amen F, Moreau F et al (2014) Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status. Eur J Cancer (Oxford, England: 1990) 50:1100–1111

  12. Samson DJ, Seidenfeld J, Ziegler K et al (2004) Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22:3618–3630

    Article  CAS  PubMed  Google Scholar 

  13. Wu B, Zhu J, Zhang Y et al (2008) Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: one institution’s experience. World J Gastroenterol 14:3064–3068

    Article  PubMed  PubMed Central  Google Scholar 

  14. Cree IA, Pazzagli M, Mini E et al (1995) Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. Anticancer Drugs 6:398–404

    Article  CAS  PubMed  Google Scholar 

  15. Mehta RS, Bornstein R, Yu IR et al (2001) Breast cancer survival and in vitro tumour response in the extreme drug resistance assay. Breast Cancer Res Treat 66:225–237

    Article  CAS  PubMed  Google Scholar 

  16. Von Hoff DD, Kronmal R, Salmon SE et al (1991) A southwest oncology group study on the use of a human tumour cloning assay for predicting response in patients with ovarian cancer. Cancer 67:20–27

    Article  Google Scholar 

  17. Suonio E, Lipponen P, Maenpaa J et al (1997) Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer. Cancer Chemother Pharmacol 41:15–21

    Article  CAS  PubMed  Google Scholar 

  18. Shaw GL, Gazdar AF, Phelps R et al (1996) Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl 24:173–185

    Article  CAS  PubMed  Google Scholar 

  19. Cortazar P, Gazdar AF, Woods E et al (1997) Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res 3:741–747

    CAS  PubMed  Google Scholar 

  20. Maurer HR, Ali-Osman F (1981) Tumour stem cell cloning in agar-containing capillaries. Naturwissenschaften 68:381–383

    Article  CAS  PubMed  Google Scholar 

  21. Ali-Osman F, Beltz PA (1988) Optimization and characterization of the capillary human tumour clonogenic cell assay. Cancer Res 48:715–724

    CAS  PubMed  Google Scholar 

  22. Von Hoff DD, Sandbach JF, Clark GM et al (1990) Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 82:110–116

    Article  Google Scholar 

  23. Weisenthal LM, Marsden JA, Dill PL et al (1983) A novel dye exclusion method for testing in vitro chemosensitivity of human tumours. Cancer Res 43:749–757

    CAS  PubMed  Google Scholar 

  24. Weisenthal LM, Dill PL, Kurnick NB et al (1983) Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res 43:258–264

    CAS  PubMed  Google Scholar 

  25. Andreotti PE, Cree IA, Kurbacher CM et al (1995) Chemosensitivity testing of human tumours using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276–5282

    CAS  PubMed  Google Scholar 

  26. Chen F, Cushion MT (1994) Use of an ATP bioluminescent assay to evaluate viability of Pneumocystis carinii from rats. J Clin Microbiol 32:2791–2800

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Ling Z, Qi C, Lu X et al (2012) Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumour chemosensitivity assay. Acta Pharmacol Sin 33:401–406

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sharma S, Neale MH, Di Nicolantonio F et al (2003) Outcome of ATP-based tumour chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3:19

    Article  PubMed  PubMed Central  Google Scholar 

  29. Meyer T, Nelstrop AE, Mahmoudi M et al (2001) Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 12:1705–1709

    Article  CAS  PubMed  Google Scholar 

  30. Kern DH, Drogemuller CR, Kennedy MC et al (1985) Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumours. Cancer Res 45:5436–5441

    CAS  PubMed  Google Scholar 

  31. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63

    Article  CAS  PubMed  Google Scholar 

  32. Furukawa T, Kubota T, Watanabe M et al (1992) High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer J Int du Cancer 51:489–498

    Article  CAS  Google Scholar 

  33. Furukawa T, Kubota T, Hoffman RM (1995) Clinical applications of the histoculture drug response assay. Clin Cancer Res 1:305–311

    CAS  PubMed  Google Scholar 

  34. Bogden AE, Kelton DE, Cobb WR, Esber HJ (1978) A rapid screening method for testing chemotherapeutic agents against human tumour xenografts. In: Houchens DP, Ovejera AA (eds) Proceedings of the symposium on the use of athymic (nude) mice in Cancer research, 1977. Fischer, New York

    Google Scholar 

  35. Singh B, Li R, Xu L et al (2002) Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24:437–442

    Article  PubMed  Google Scholar 

  36. Hasegawa Y, Goto M, Hanai N et al (2007) Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43:749–756

    Article  CAS  PubMed  Google Scholar 

  37. Schuler PJ, Trellakis S, Greve J et al (2010) In vitro chemosensitivity of head and neck cancer cell lines. Eur J Med Res 15:337–344

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Hoffmann TK, Sonkoly E, Hauser U et al (2008) Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 44:1100–1109

    Article  CAS  PubMed  Google Scholar 

  39. Martens-de Kemp SR, Dalm SU, Wijnolts FMJ et al (2013) DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. PLoS ONE 8:e61555

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Erjala K, Raitanen M, Kulmala J et al (2007) Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 133:169–176

    Article  CAS  PubMed  Google Scholar 

  41. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 359:1116–1127

    Article  CAS  PubMed  Google Scholar 

  42. Seiwert TY, Haddad RI, Gupta S et al (2015) Antitumour activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort. ASCO Meet Abstr 33:LBA6008

  43. Dollner R, Granzow C, Helmke BM et al (2004) The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res 24:325–331

    PubMed  Google Scholar 

  44. Dollner R, Granzow C, Neudert M et al (2006) Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Anticancer Res 26:1651–1655

    CAS  PubMed  Google Scholar 

  45. Bogden AE, Von Hoff DD (1984) Comparison of the human tumour cloning and subrenal capsule assays. Cancer Res 44:1087–1090

    CAS  PubMed  Google Scholar 

  46. Rhedin AS, Tidefelt U, Jonsson K et al (1993) Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk Res 17:271–276

    Article  CAS  PubMed  Google Scholar 

  47. Ole Thastrup. ICSC (integrated chemical synthesis and screening in patient cells). Im Internet: http://cordis.europa.eu/result/rcn/58199_en.html. Accessed 14 Sep 2014

  48. Broder GR, Birtwell SW, Hagel G, Thastrup O, Morgan H, Roach PL (2011) Multiplex bioassays using a suspension array platform; towards the high throughput screening of drugs targeting cancer stem cells. In: Verpoorte S, Hrsg (eds) 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2010. (MicroTAS 2010): Groningen, The Netherlands, 3–7 October 2010. San Diego, Calif., Red Hook, NY: Chemical and Biological Microsystems Society; Printed from e-media with permission by Curran Associates, Inc., vol c2010, pp 185–1387

  49. Horizon 2020 newsroom editor. Better combination therapies for colorectal cancer patients. http://ec.europa.eu/programmes/horizon2020/en/news/better-combination-therapies-colorectal-cancer-patients. Accessed 14 Sep 2015

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rainald Knecht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bussmann, L., Busch, CJ., Lörincz, B.B. et al. Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer. Eur Arch Otorhinolaryngol 273, 4073–4080 (2016). https://doi.org/10.1007/s00405-015-3893-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-015-3893-1

Keywords

Navigation